Certolizumab Pegol
Indication
Non-radiographic axial spondyloarthritis (NICE TA383)
Red
Brand:
Cimzia®
Nice TA:
383
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Musculoskeletal system
Background
Certolizumab is recommended, within its marketing authorisations, as an option for treating severe non-radiographic axial spondyloarthritis in adults whose disease has responded inadequately to, or who cannot tolerate, non‑steroidal anti‑inflammatory drugs.
Recommendation
LSCMMG Recommendation:
Red
Reason for decision:
Specialist medicine
Supporting documents: